The Latest Breaking News from Sanofi

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of all regular shares that are available for trading.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Reuters

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.  "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

(Fixes typographical error in media identifier)

Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work.

Novavax now in financial trouble after missing peak vaccinations

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Antifungals also needed, says study, as drug resistance has increased faster than expected, particularly in sub-Saharan Africa